Participants will:
-
Understand the significance of EGFR mutations and the evolving landscape of targeted therapy in NSCLC.
-
Explore how these therapies work and the importance of matching treatment to tumour biology.
-
Gain strategies for patient education and communication, including explaining treatment goals in plain language.
-
Learn how to monitor and manage early toxicities and support adherence and wellbeing across the treatment continuum.
-
Apply insights through case-based learning to reinforce clinical decision-making and supportive care principles.
